Medtronic's $550 Million Scientia Vascular Deal Aims To Boost Neurovascular Portfolio - Medtronic (NYSE:MDT)

Medtronic's $550 Million Scientia Vascular Deal Aims To Boost Neurovascular Portfolio - Medtronic (NYSE:MDT)

Medtronic plc (NYSE:MDT) shares are down on Tuesday as the company announced plans to acquire Scientia Vascular, a move aimed at enhancing its neurovascular portfolio. This decline comes as broader markets are experiencing a downturn, with major indices like the S&P 500 and Nasdaq both in the red. $550 Million Deal The acquisition is expected to strengthen Medtronic’s position in the neurovascular space, integrating Scientia’s access and therape…

Medtronic to acquire Scientia Vascular for $550M

The Scientia deal follows Medtronic’s announcement in February that it’ll acquire CathWorks for up to $585 million.

Medtronic to buy Scientia Vascular in $550 million deal

March 10 (Reuters) – Medical device maker Medtronic said on Tuesday it has agreed to buy ​U.S.-based Scientia Vascular in a ‌deal valued at $550 million, aiming to expand its line-up of products used in stroke care. Here are some details: (Reporting by Sahil Pandey in Bengaluru; Editing by ​Jonathan Ananda)

Medtronic to Buy Scientia Vascular in $550 Million Neurovascular Deal

In a move poised to reshape the future of stroke treatment technology, Medtronic to buy Scientia Vascular marks a major step toward expanding innovation in neurovascular care. The global medical technology leader announced it has signed a definitive agreement to acquire the private company for $550 million, subject to customary adjustments. The deal could also include additional undisclosed milestone and earn-out payments following completion of…